2023 Guidelines on the Diagnosis and Treatment of Insomnia in Adults - Brazilian Sleep Association
Open accessThe DOI matches its Crossref record; 266 of the 268 references it cites were found in a registry or an index.
Abstract
Chronic insomnia disorder (simplified in this document as insomnia) is an increasingly common clinical condition in society and a frequent complaint at the offices of different areas of health practice (particularly Medicine and Psychology). This scenario has been accompanied by a significant evolution in treatment, as well as challenges in approaching patients in an appropriately way. This clinical guideline, coordinated by the Brazilian Sleep Association and the Brazilian Association of Sleep Medicine and counting on the active participation of various specialists in the area, encompasses an update on the diagnosis and treatment of insomnia in adults. To this end, it followed a structured methodology. Topics of interest related to diagnosis were written based on theoretical framework, evidence in the literature, and professional experience. As for the topics related to the treatment of insomnia, a series of questions were developed based on the PICO acronym (P – Patient, problem, or population; I – Intervention; C – Comparison, control, or comparator; O – Outcome). The work groups defined the eligible options within each of these parameters. Regarding pharmacological interventions, only the ones currently available in Brazil or possibly becoming available in the upcoming years were considered eligible. Systematic reviews were conducted to help prepare the texts and define the level of evidence for each intervention. The final result is an objective and practical document providing recommendations with the best scientific support available to professionals involved in the management of insomnia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“With increased Z-drug use, a range of serious adverse effects has been identified, including delirium, sleep-related eating disorder, amnesia, and complex behaviors such as sleep-driving; these effects may occur at therapeutic doses, and they are intensified by alcohol or other sedatives.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In contrast, eszopiclone has demonstrated safety for up to 12 months in primary insomnia patients.”
From Z-drug abuse and dependence: Clinical guideline of the Brazilian Academy of Neurology for diagnosis and management (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research
Buysse, D. J., Reynolds, C. F., Monk, T. H., Berman, S. R., & Kupfer, D. J. (1989) · Psychiatry Research · doi:10.1016/0165-1781(89)90047-4 · Cited by 35,234
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
DrugBank 5.0: a major update to the DrugBank database for 2018
Wishart, D. S., Feunang, Y. D., Guo, A. C., Lo, E. J., Marcu, A., Grant, J. R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1037 · Cited by 8,404 · cited 2×
“164 BZDs can exacerbate symptomssuch as respiratory depression, incoordination and imbalance, behavioral changes, and sleepiness.”
BackgroundValidation of the Insomnia Severity Index as an outcome measure for insomnia research
Bastien, C. (2001) · Sleep Medicine · doi:10.1016/s1389-9457(00)00065-4 · Cited by 8,067 · cited 1×
“30 2.”
The International Classification of Sleep Disorders: Diagnostic and Coding Manual
Daroff, R. B. (1991) · Neurology · doi:10.1212/wnl.41.1.160 · Cited by 5,014
Diamond, I. R., Grant, R. C., Feldman, B. M., Pencharz, P. B., Ling, S. C., Moore, A. M., & Wales, P. W. (2014) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.12.002 · Cited by 3,740
The consensus sleep diary: standardizing prospective sleep self-monitoring
Carney, C. E., Buysse, D. J., Ancoli-Israel, S., Edinger, J. D., Krystal, A. D., Lichstein, K. L., & Morin, C. M. (2012) · Sleep · doi:10.5665/sleep.1642 · Cited by 2,172 · cited 2×
“29 The patient must be instructed to fi ll it out every day, preferably no more than 1hour after waking up in the morning.”
BackgroundCannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169
European guideline for the diagnosis and treatment of insomnia
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., et al. (2017) · Journal of Sleep Research · doi:10.1111/jsr.12594 · Cited by 2,049
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965
Clinical Guideline for the Evaluation and Management of Chronic Insomnia in Adults
Schutte-Rodin, S., Broch, L., Buysse, D., Dorsey, C., & Sateia, M. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27286 · Cited by 1,943
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
A behavioral perspective on insomnia treatment
Spielman, A. J., Caruso, L. S., & Glovinsky, P. B. (1987) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(18)30532-x · Cited by 1,261 · cited 1×
“46 Based on this model, CBT-I explains the vicious cycle of insomnia perpet-uated by the impairment of the homeostatic sleep pressure, the disorganization of the circadian rhythm, and the wake-fulness conditioned by associations between the environment, cognitive and somatic excitability, and…”
BackgroundValidation of the Brazilian Portuguese version of the Pittsburgh sleep quality index
Bertolazi, A. N., Fagondes, S. C., Hoff, L. S., Dartora, E. G., da Silva Miozzo, I. C., de Barba, M. E. F., & Menna Barreto, S. S. (2011) · Sleep Medicine · doi:10.1016/j.sleep.2010.04.020 · Cited by 1,211
Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis
Trauer, J. M., Qian, M. Y., Doyle, J. S., Rajaratnam, S. M. W., & Cunnington, D. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2841 · Cited by 1,053 · cited 2×
“50,64,83 These effects are long-lasting and independent of comorbidity, age, and sex, 49,64,92 especially in the presence of clinical support during follow-up.”
BackgroundMethodMorin, C. M., & Jarrin, D. C. (2022) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2022.03.003 · Cited by 907
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
Huang, C., Huang, L., Wang, Y., Li, X., Ren, L., Gu, X., Kang, L., Guo, L., Liu, M., Zhou, X., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00810-3 · Cited by 898
Edinger, J. D., Arnedt, J. T., Bertisch, S. M., Carney, C. E., Harrington, J. J., Lichstein, K. L., Sateia, M. J., Troxel, W. M., Zhou, E. S., Kazmi, U., et al. (2021) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.8986 · Cited by 807
Zachariae, R., Lyby, M. S., Ritterband, L. M., & O'Toole, M. S. (2016) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2015.10.004 · Cited by 704
Cognitive and behavioral therapies in the treatment of insomnia: A meta-analysis
van Straten, A., van der Zweerde, T., Kleiboer, A., Cuijpers, P., Morin, C. M., & Lancee, J. (2018) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2017.02.001 · Cited by 676 · cited 2×
“It can include a communication channel with a specialist professional (email or chat inserted in the application/system).”
BackgroundMelatonin as a Hormone: New Physiological and Clinical Insights
Cipolla-Neto, J., & Amaral, F. G. D. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00084 · Cited by 635
Wilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Portuguese-language version of the Epworth sleepiness scale: validation for use in Brazil
Bertolazi, A. N., Fagondes, S. C., Hoff, L. S., Pedro, V. D., Menna Barreto, S. S., & Johns, M. W. (2009) · Jornal Brasileiro de Pneumologia · doi:10.1590/s1806-37132009000900009 · Cited by 630
Krystal, A. D., Walsh, J. K., Laska, E., Caron, J., Amato, D. A., Wessel, T. C., & Roth, T. (2003) · Sleep · doi:10.1093/sleep/26.7.793 · Cited by 630 · cited 2×
“The perception of medical societyabout these drugs began to change after the second half of the 1970s and into the following decade due to side effects, mainlyabuse, addiction, and accidents.”
BackgroundEdinger, J. D., Wohlgemuth, W. K., Radtke, R. A., Marsh, G. R., & Quillian, R. E. (2001) · JAMA · doi:10.1001/jama.285.14.1856 · Cited by 625 · cited 1×
“47,50,53,80 – 83 ► Table 12 presents these effects and the ones measured with PSG. 54,84 The effects of CBT-I on increasing TST are evident in some studies, with sensitivity indicated by the sleep diary 50,62,64,66,83,85 and PSG, 62,84 though with no such correspondence in actigraphy analysis.”
BackgroundBinding of antipsychotic drugs to human brain receptors
Richelson, E., & Souder, T. (2000) · Life Sciences · doi:10.1016/s0024-3205(00)00911-5 · Cited by 607
The benzodiazepine binding site of GABAA receptors
Sigel, E. (1997) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(97)01118-8 · Cited by 594
Benzodiazepines revisited—will we ever learn?
Lader, M. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03563.x · Cited by 573 · cited 3×
“162,163 Dual Orexin Receptor Antagonists (DORA) Orexins or hypocretins are hypothalamic neuropeptides that have a role in regulating the sleep-wake cycle and maintaining wakefulness.”
BackgroundBrain mechanisms of insomnia: new perspectives on causes and consequences
Van Someren, E. J. W. (2021) · Physiological Reviews · doi:10.1152/physrev.00046.2019 · Cited by 543 · cited 1×
“…cycle of insomnia perpet-uated by the impairment of the homeostatic sleep pressure, the disorganization of the circadian rhythm, and the wake-fulness conditioned by associations between the environment, cognitive and somatic excitability, and dysfunctional beliefs and thought patterns about sleep.”
BackgroundNeurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist
Kato, K., Hirai, K., Nishiyama, K., Uchikawa, O., Fukatsu, K., Ohkawa, S., Kawamata, Y., Hinuma, S., & Miyamoto, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.09.007 · Cited by 539
Michelson, D., Snyder, E., Paradis, E., Chengan-Liu, M., Snavely, D. B., Hutzelmann, J., Walsh, J. K., Krystal, A. D., Benca, R. M., Cohn, M., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70053-5 · Cited by 519
Smith, M. T., McCrae, C. S., Cheung, J., Martin, J. L., Harrod, C. G., Heald, J. L., & Carden, K. A. (2018) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.7230 · Cited by 483
Soh, H. L., Ho, R. C., Ho, C. S., & Tam, W. W. (2020) · Sleep Medicine · doi:10.1016/j.sleep.2020.08.020 · Cited by 482
Methodology Update: Delphi Studies
McPherson, S., Reese, C., & Wendler, M. C. (2018) · Nursing Research · doi:10.1097/nnr.0000000000000297 · Cited by 467
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
Molecular pharmacology regulation and function of mammalian melatonin receptors
Dubocovich, M. L. (2003) · Frontiers in Bioscience · doi:10.2741/1089 · Cited by 451
Risk of first‐generation H 1 ‐antihistamines: a GA 2 LEN position paper
Church, M. K., Maurer, M., Simons, F. E. R., Bindslev‐Jensen, C., Van Cauwenberge, P., Bousquet, J., Holgate, S. T., & Zuberbier, T. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02325.x · Cited by 440
Auger, R. R., Burgess, H. J., Emens, J. S., Deriy, L. V., Thomas, S. M., & Sharkey, K. M. (2015) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.5100 · Cited by 438
An efficacy, safety, and dose–response study of Ramelteon in patients with chronic primary insomnia
ERMAN, M., SEIDEN, D., ZAMMIT, G., SAINATI, S., & ZHANG, J. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2005.09.004 · Cited by 434
Rosenberg, R., Murphy, P., Zammit, G., Mayleben, D., Kumar, D., Dhadda, S., Filippov, G., LoPresti, A., & Moline, M. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.18254 · Cited by 412
Perlis, M. L., Posner, D., Riemann, D., Bastien, C. H., Teel, J., & Thase, M. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00879-0 · Cited by 395
Antidepressants and Sleep: A Qualitative Review of the Literature
Wilson, S., & Argyropoulos, S. (2005) · Drugs · doi:10.2165/00003495-200565070-00003 · Cited by 392 · cited 1×
“237 Considering its pharmacokinetic and pharmacodynamic characteristics, the sedative effect of amitriptyline occurs with doses considered subtherapeutic for depression, around 25 and 25mg used near the intended time for sleep.”
BackgroundDrugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Atkin, T., Comai, S., & Gobbi, G. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014381 · Cited by 391 · cited 4×
“Thus, one can understand the various pro fi les of adverse effects such as sedation, hypotension, extrapyramidal symptoms, dystonia, hyperprolactinemia, and so on, which should be considered when prescribing medications of this class.”
BackgroundInfluentialOrexin Receptors: Pharmacology and Therapeutic Opportunities
Scammell, T. E., & Winrow, C. J. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100528 · Cited by 381
Improving sleep with mindfulness and acceptance: a metacognitive model of insomnia
Ong, J. C., Ulmer, C. S., & Manber, R. (2012) · Behaviour Research and Therapy · doi:10.1016/j.brat.2012.08.001 · Cited by 376
Léger, D., & Bayon, V. (2010) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2010.01.003 · Cited by 376
Lewy, A. J., Bauer, V. K., Ahmed, S., Thomas, K. H., Cutler, N. L., Singer, C. M., Moffit, M. T., & Sack, R. L. (1998) · Chronobiology International · doi:10.3109/07420529808998671 · Cited by 363 · cited 1×
“19,20,221 There are no speci fi c contraindications for different age groups and can also be used in adults over 65 years.”
BackgroundA meta-analysis of group cognitive behavioral therapy for insomnia
Koffel, E. A., Koffel, J. B., & Gehrman, P. R. (2015) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2014.05.001 · Cited by 356 · cited 5×
“83 Compared with a waiting list and a psychoeducation con-trol group, ACT reduced the severity of insomnia 55,68 and improved sleep parameters and secondary outcomes such as dysfunctional beliefs and attitudes about sleep, acceptance of sleep problems, daytime sleepiness, and cognitive suppression.”
BackgroundMethodInfluentialPractice Parameters for Using Polysomnography to Evaluate Insomnia: An Update
Littner, M., Hirshkowitz, M., Kramer, M., Kapen, S., Anderson, W. M., Bailey, D., Berry, R. B., Davila, D., Johnson, S., Kushida, C., et al. (2003) · Sleep · doi:10.1093/sleep/26.6.754 · Cited by 346 · cited 2×
“…are indicated to perform PSGtodiagnoseinsomnia:(a)toexcludeothersleepdisorders, such as obstructive sleep apnea (OSA) and periodic limb movements 27 ; (b) to objectively assess sleep-onset latency, total sleep time (TST), the number of wakes, sleep ef fi ciency, duration of the stages, and wake…”
BackgroundInsomnia disorder: State of the science and challenges for the future
Riemann, D., Benz, F., Dressle, R. J., Espie, C. A., Johann, A. F., Blanken, T. F., Leerssen, J., Wassing, R., Henry, A. L., Kyle, S. D., et al. (2022) · Journal of Sleep Research · doi:10.1111/jsr.13604 · Cited by 343 · cited 2×
“Hence, there is an evident need for a new version of the Brazilian Consensus on Insomnia, meeting the needs of trained and specialized Sleep Medicine professionals and all other ones Kaur 12 and Riemann and colleagues 5 ).”
Backgroundvan der Zweerde, T., Bisdounis, L., Kyle, S. D., Lancee, J., & van Straten, A. (2019) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2019.08.002 · Cited by 336 · cited 1×
“It can include a communication channel with a specialist professional (email or chat inserted in the application/system).”
BackgroundA Randomized Controlled Trial of Mindfulness Meditation for Chronic Insomnia
Ong, J. C., Manber, R., Segal, Z., Xia, Y., Shapiro, S., & Wyatt, J. K. (2014) · Sleep · doi:10.5665/sleep.4010 · Cited by 332
Garland, S. N., Carlson, L. E., Stephens, A. J., Antle, M. C., Samuels, C., & Campbell, T. S. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7265 · Cited by 329
Seyffert, M., Lagisetty, P., Landgraf, J., Chopra, V., Pfeiffer, P. N., Conte, M. L., & Rogers, M. A. M. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149139 · Cited by 323 · cited 4×
“…with control conditions and isolated CBT-I techniques, multicomponent CBT-I has also been shown to improve daytime symptoms such as fatigue and sleepiness, 80,88,89 as well as symptoms of anxiety, depression, and/or stress 82,83,85,88,89 and dysfunctional beliefs and attitudes toward sleep.”
BackgroundMethodInfluentialClinical pharmacokinetics of melatonin: a systematic review
Harpsøe, N. G., Andersen, L. P. H., Gögenur, I., & Rosenberg, J. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1873-4 · Cited by 322 · cited 1×
“207,208 Patient assessment: There is no consistent evidence supporting melatonin use to treat insomnia in healthy young adults.”
BackgroundSleep hygiene education as a treatment of insomnia: a systematic review and meta-analysis
Chung, K.-F., Lee, C.-T., Yeung, W.-F., Chan, M.-S., Chung, E. W.-Y., & Lin, W.-L. (2018) · Family Practice · doi:10.1093/fampra/cmx122 · Cited by 313 · cited 2×
“The sleep hygiene approach alone has limited clinical outcomes in improving primary chronic insomnia when compared with control, 52,91 with no effect on comorbid insomnia or when compared with CBT-I and mindfulness approaches for treating insomnia.”
BackgroundWilson, S., Anderson, K., Baldwin, D., Dijk, D.-J., Espie, A., Espie, C., Gringras, P., Krystal, A., Nutt, D., Selsick, H., et al. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881119855343 · Cited by 312
Efficacy and safety of eszopiclone across 6-weeks of treatment for primary insomnia
Zammit, G. K., McNabb, L. J., Caron, J., Amato, D. A., & Roth, T. (2004) · Current Medical Research and Opinion · doi:10.1185/174234304x15174 · Cited by 294
The Benzodiazepine Binding Sites of GABAA Receptors
Sigel, E., & Ernst, M. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.006 · Cited by 287 · cited 1×
“167,168 Outcomes such as sleep onset latency, TST, WASO reduction, maintenance of sleep architecture, as well as global and patient clinical impression, have been systematically evaluated with suvorexant in placebo-controlled trials involving more than 1,000 patients.”
MethodGreenblatt, D. J., & Roth, T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.667074 · Cited by 283
Hartescu, I., Morgan, K., & Stevinson, C. D. (2015) · Journal of Sleep Research · doi:10.1111/jsr.12297 · Cited by 273 · cited 1×
“115 More recently, Baron and colleagues showed that moderate to vigorous aerobic training for 12 weeks also improved the severity of insomnia symptoms.”
BackgroundErland, L. A. E., & Saxena, P. K. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6462 · Cited by 273
Sleep Medicine: Insomnia and Sleep.
Bollu, P. C., & Kaur, H. (2019) · Europe PMC (PubMed Central) · Cited by 269
Ong, J. C., Shapiro, S. L., & Manber, R. (2008) · Behavior Therapy · doi:10.1016/j.beth.2007.07.002 · Cited by 268
Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia
Roth, T., Seiden, D., Sainati, S., Wang-Weigand, S., Zhang, J., & Zee, P. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2006.01.003 · Cited by 265
Griffiths, R. R., & Johnson, M. W. (2005) · PubMed · Cited by 260
Baglioni, C., Altena, E., Bjorvatn, B., Blom, K., Bothelius, K., Devoto, A., Espie, C. A., Frase, L., Gavriloff, D., Tuuliki, H., et al. (2020) · Journal of Sleep Research · doi:10.1111/jsr.12967 · Cited by 259
Gross, C. R., Kreitzer, M. J., Reilly-Spong, M., Wall, M., Winbush, N. Y., Patterson, R., Mahowald, M., & Cramer-Bornemann, M. (2011) · EXPLORE · doi:10.1016/j.explore.2010.12.003 · Cited by 249 · cited 1×
“Studies involving mindfulness-based intervention protocols compared with controls demonstrate improvements in ISI, 56,95 – 97 PSQI, 97 – 99 and subjective sleep parameters: sleep latency, sleep ef fi ciency, WASO, 97,98 with improvement in mental health parameters during follow-up.”
MethodThe Absolute Bioavailability of Oral Melatonin
DeMuro, R. L., Nafziger, A. N., Blask, D. E., Menhinick, A. M., & Bertino, J. S. (2000) · The Journal of Clinical Pharmacology · doi:10.1177/00912700022009422 · Cited by 242 · cited 2×
“207,208 Patient assessment: There is no consistent evidence supporting melatonin use to treat insomnia in healthy young adults.”
BackgroundSecond-Generation Antihistamines: A Comparative Review
Slater, J. W., Zechnich, A. D., & Haxby, D. G. (1999) · Drugs · doi:10.2165/00003495-199957010-00004 · Cited by 241
Self-help cognitive-behavioral therapy for insomnia: A meta-analysis of randomized controlled trials
Ho, F. Y.-Y., Chung, K.-F., Yeung, W.-F., Ng, T. H., Kwan, K.-S., Yung, K.-P., & Cheng, S. K. (2015) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2014.06.010 · Cited by 239 · cited 2×
“…with control conditions and isolated CBT-I techniques, multicomponent CBT-I has also been shown to improve daytime symptoms such as fatigue and sleepiness, 80,88,89 as well as symptoms of anxiety, depression, and/or stress 82,83,85,88,89 and dysfunctional beliefs and attitudes toward sleep.”
BackgroundMethodThe History of Benzodiazepines
Wick, J. Y. (2013) · The Consultant Pharmacist · doi:10.4140/tcp.n.2013.538 · Cited by 231
ROTH, T., WALSH, J., KRYSTAL, A., WESSEL, T., & ROEHRS, T. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2005.06.004 · Cited by 230
Mindfulness meditation for insomnia: A meta-analysis of randomized controlled trials
Gong, H., Ni, C.-X., Liu, Y.-Z., Zhang, Y., Su, W.-J., Lian, Y.-J., Peng, W., & Jiang, C.-L. (2016) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2016.07.016 · Cited by 230 · cited 1×
“Studies involving mindfulness-based intervention protocols compared with controls demonstrate improvements in ISI, 56,95 – 97 PSQI, 97 – 99 and subjective sleep parameters: sleep latency, sleep ef fi ciency, WASO, 97,98 with improvement in mental health parameters during follow-up.”
MethodHuman Phase Response Curves to Three Days of Daily Melatonin: 0.5 mg Versus 3.0 mg
Burgess, H. J., Revell, V. L., Molina, T. A., & Eastman, C. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2590 · Cited by 221
Krystal, A. D., Erman, M., Zammit, G. K., Soubrane, C., & Roth, T. (2008) · Sleep · doi:10.1093/sleep/31.1.79 · Cited by 212
Xie, Y., Liu, S., Chen, X.-J., Yu, H.-H., Yang, Y., & Wang, W. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.664499 · Cited by 208 · cited 1×
“119,120 Mind-body techniques Mind-body techniques include meditative practices, yoga, Tai Chi, qigong, and so forth.”
Background(2009) · Focus · doi:10.1176/foc.7.4.foc538 · Cited by 208 · cited 1×
“35 All these indications can be useful in the treatment with CBT-I 21,27,28 and must be considered according to the clinical judgment of each case.”
The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases
Wang, C., Wang, Q., Ji, B., Pan, Y., Xu, C., Cheng, B., Bai, B., & Chen, J. (2018) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2018.00220 · Cited by 207
Hajak, G., Rodenbeck, A., Voderholzer, U., Riemann, D., Cohrs, S., Hohagen, F., Berger, M., & Ruther, E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0609 · Cited by 199 · cited 1×
“224 – 228 The systematic review published in 2015 with RCTs comparing doxepin with placebo 229 concluded that doxepin had a mean effect size compared with placebo for sleep maintenance and sleep duration, without signi fi cant residue the next day, being considered safe and effective, particularly…”
BackgroundRamelteon for the treatment of insomnia in adults: a systematic review and meta-analysis
Kuriyama, A., Honda, M., & Hayashino, Y. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2013.11.788 · Cited by 198
Antidepressants for insomnia in adults
Everitt, H., Baldwin, D. S., Stuart, B., Lipinska, G., Mayers, A., Malizia, A. L., Manson, C. C., & Wilson, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010753.pub2 · Cited by 198 · cited 10×
“221,222 High-quality antide-pressants for insomnia treatment are required.”
BackgroundInfluentialEvaluation of the Efficacy and Safety of Ramelteon in Subjects with Chronic Insomnia
Zammit, G., Erman, M., Wang-Weigand, S., Sainati, S., Zhang, J., & Roth, T. (2007) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.26914 · Cited by 197
Krystal, A. D., Durrence, H. H., Scharf, M., Jochelson, P., Rogowski, R., Ludington, E., & Roth, T. (2010) · Sleep · doi:10.1093/sleep/33.11.1553 · Cited by 193
Chesson, A. L., Hartse, K. M., Anderson, W. M., Davila, D., Johnson, S. F., Littner, M. R., Wise, M. S., & Rafecas, J. (2000) · PubMed · Cited by 193
Valerian for insomnia: a systematic review of randomized clinical trials
Stevinson, C. (2000) · Sleep Medicine · doi:10.1016/s1389-9457(99)00015-5 · Cited by 193
Morin, C. M., Koetter, U., Bastien, C., Ware, J. C., & Wooten, V. (2005) · Sleep · doi:10.1093/sleep/28.11.1465 · Cited by 190 · cited 1×
“271,272 Off-label use of this class can generate residual symptoms the next day and compromise everyday situations (re fl exes, ability to drive, etc.).”
BackgroundEffectiveness of Valerian on insomnia: A meta-analysis of randomized placebo-controlled trials
Fernández-San-Martín, M. I., Masa-Font, R., Palacios-Soler, L., Sancho-Gómez, P., Calbó-Caldentey, C., & Flores-Mateo, G. (2010) · Sleep Medicine · doi:10.1016/j.sleep.2009.12.009 · Cited by 187
Changes During Weeks in Effects of Tricyclic Drugs on the Human Sleeping Brain
Dunleavy, D. L. F., Brezinova, V., Oswald, I., Maclean, A. W., & Tinker, M. (1972) · British Journal of Psychiatry · doi:10.1192/bjp.120.559.663 · Cited by 180 · cited 1×
“240 It is important to emphasize that tricyclic anti-depressants suppress REM sleep and are associated with the triggering or aggravation of periodic limb movements, restless leg syndrome, and REM sleep behavioral disorder.”
BackgroundWade, A. G., Ford, I., Crawford, G., McConnachie, A., Nir, T., Laudon, M., & Zisapel, N. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-51 · Cited by 178 · cited 1×
“Due to the very high af fi nity of doxepin by the H1 receiver, its effect as a selective antagonist of the H1 receiver can be ensured when used at low doses and promoting its hypnotic action (1 to 6mg of doxepin as a hypnotic, compared with 150 to 300 mg of doxepin as an antidepressant).”
BackgroundKärppä, M., Yardley, J., Pinner, K., Filippov, G., Zammit, G., Moline, M., Perdomo, C., Inoue, Y., Ishikawa, K., & Kubota, N. (2020) · Sleep · doi:10.1093/sleep/zsaa123 · Cited by 177 · cited 1×
“Ramelteon has also been associated with improving persistent sleep latency (time from lights off to the fi rst sleep lasting at least 10minutes), improving sleep ef fi ciency, and objective TST. Drug interactions, contraindications, and side effects: When co-administered with ramelteon, fl uvoxamine…”
BackgroundWang, W.-L., Chen, K.-H., Pan, Y.-C., Yang, S.-N., & Chan, Y.-Y. (2020) · BMC Psychiatry · doi:10.1186/s12888-020-02566-4 · Cited by 176
Insomnia in Elderly Patients: Recommendations for Pharmacological Management
Abad, V. C., & Guilleminault, C. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0569-8 · Cited by 174 · cited 1×
“221,223 Unlike other tricyclic antidepressants, doxepin does not pose a risk of worsening symptoms of restless leg syndrome or periodic limb movement disorder.”
BackgroundRios Romenets, S., Creti, L., Fichten, C., Bailes, S., Libman, E., Pelletier, A., & Postuma, R. B. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2013.03.003 · Cited by 166
Winokur, A., DeMartinis, N. A., McNally, D. P., Gary, E. M., Cormier, J. L., & Gary, K. A. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n1013 · Cited by 165
Horsch, C. H., Lancee, J., Griffioen-Both, F., Spruit, S., Fitrianie, S., Neerincx, M. A., Beun, R. J., & Brinkman, W.-P. (2017) · Journal of Medical Internet Research · doi:10.2196/jmir.6524 · Cited by 164
Kolla, B. P., Mansukhani, M. P., & Bostwick, J. M. (2017) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2017.06.002 · Cited by 162
Besag, F. M. C., Vasey, M. J., Lao, K. S. J., & Wong, I. C. K. (2019) · CNS Drugs · doi:10.1007/s40263-019-00680-w · Cited by 162 · cited 2×
“It is important to clarify that indicating the use of sedative antidepressants to treat insomnia is independent of the presence of psychiatric comorbidity and that the doses used for this purpose are signi fi cantly lower than those originally recommended to treat depression.”
BackgroundZick, S. M., Wright, B. D., Sen, A., & Arnedt, J. T. (2011) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-11-78 · Cited by 157
Duration, timing and quality of sleep are each vital for health, performance and safety
Czeisler, C. A. (2015) · Sleep Health · doi:10.1016/j.sleh.2014.12.008 · Cited by 156 · cited 1×
“168 A review that included 1,824 patients using suvorexant revealed signi fi cant improvement in sleep, as assessed with ISI when compared with the placebo group.”
MethodHong, J. S. W., Atkinson, L. Z., Al‐Juffali, N., Awad, A. M. M., Geddes, J. R., Tunbridge, E. M., Harrison, P. J., & Cipriani, A. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01386-6 · Cited by 149
Mayer, G., Wang-Weigand, G., Roth‐Schechter, B. F., Lehmann, R., Staner, C., & Partinen, M. (2009) · SLEEP · doi:10.1093/sleep/32.3.351 · Cited by 145
Ree, M., Junge, M., & Cunnington, D. (2017) · Sleep Medicine · doi:10.1016/j.sleep.2017.03.017 · Cited by 145
Better than sham? A double-blind placebo-controlled neurofeedback study in primary insomnia
Schabus, M., Griessenberger, H., Gnjezda, M.-T., Heib, D. P. J., Wislowska, M., & Hoedlmoser, K. (2017) · Brain · doi:10.1093/brain/awx011 · Cited by 144
Humphrey-Murto, S., Wood, T. J., Gonsalves, C., Mascioli, K., & Varpio, L. (2020) · Academic Medicine · doi:10.1097/acm.0000000000002887 · Cited by 136
Objective prevalence of insomnia in the São Paulo, Brazil epidemiologic sleep study
Castro, L. S., Poyares, D., Leger, D., Bittencourt, L., & Tufik, S. (2013) · Annals of Neurology · doi:10.1002/ana.23945 · Cited by 135
Self-citationSoares, C. N., Joffe, H., Rubens, R., Caron, J., Roth, T., & Cohen, L. (2006) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000245449.97365.97 · Cited by 135
Simon, L., Steinmetz, L., Feige, B., Benz, F., Spiegelhalder, K., & Baumeister, H. (2023) · Scientific Reports · doi:10.1038/s41598-023-28853-0 · Cited by 132
Walsh, J. H., Maddison, K. J., Rankin, T., Murray, K., McArdle, N., Ree, M. J., Hillman, D. R., & Eastwood, P. R. (2021) · SLEEP · doi:10.1093/sleep/zsab149 · Cited by 130 · cited 1×
“Herbal or herbal products should not be used by pregnant or breastfeeding women, as there are no adequate and well-controlled safety and toxicity studies in these conditions.”
BackgroundDoxepin for insomnia: A systematic review of randomized placebo-controlled trials
Yeung, W.-F., Chung, K.-F., Yung, K.-P., & Ng, T. H.-Y. (2015) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2014.06.001 · Cited by 126
AminiLari, M., Wang, L., Neumark, S., Adli, T., Couban, R., Giangregorio, A., Carney, C. E., & Busse, J. W. (2021) · SLEEP · doi:10.1093/sleep/zsab234 · Cited by 124 · cited 2×
“257 – 260 A meta-analysis with 219 adult patients with insomnia, evaluating objective (PSG or actigraphy) and subjective outcomes, showed that the use of cannabinoid,CBD,andTHC-analogousextracts,improvedPSQI sleepquality by upto 8 weeks.”
BackgroundWinokur, A., Sateia, M. J., Hayes, J. B., Bayles-Dazet, W., MacDonald, M. M., & Gary, K. A. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00882-9 · Cited by 123
Beuckmann, C. T., Suzuki, M., Ueno, T., Nagaoka, K., Arai, T., & Higashiyama, H. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241422 · Cited by 123
Roth, T. G., Soubrane, C., Titeux, L., & Walsh, J. K. (2006) · Sleep Medicine · doi:10.1016/j.sleep.2006.04.008 · Cited by 121
Chen, T.-L., Chang, S.-C., Hsieh, H.-F., Huang, C.-Y., Chuang, J.-H., & Wang, H.-H. (2020) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2020.110144 · Cited by 118 · cited 5×
“56,57 This chapter aims to recommend the approaches with the highest level of scienti fi c evidence for clinical outcomes and follow-up, considering objective parameters assessed with PSG and actigraphy and subjective ones obtained from sleep diaries and questionnaires that assess the severity of…”
BackgroundMethodResultInfluentialYe, Y.-Y., Chen, N.-K., Chen, J., Liu, J., Lin, L., Liu, Y.-Z., Lang, Y., Li, X.-J., Yang, X.-J., & Jiang, X.-J. (2016) · BMJ Open · doi:10.1136/bmjopen-2015-010707 · Cited by 115
Benzodiazepines: More Behavioural Addiction than Dependence
de las Cuevas, C., Sanz, E., & de la Fuente, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1376-8 · Cited by 113 · cited 1×
“There is no signi fi cantdifferencebetweenyoung people and older adults in relation to the risk of adverse effects.”
BackgroundTreatment Effects of Gabapentin for Primary Insomnia
Lo, H.-S., Yang, C.-M., Lo, H. G., Lee, C.-Y., Ting, H., & Tzang, B.-S. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cda242 · Cited by 110
Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials
Yi, X.-Y., Ni, S., Ghadami, M. R., Meng, H., Chen, M., Kuang, L., Zhang, Y., Zhang, L., & Zhou, X. (2018) · Sleep Medicine · doi:10.1016/j.sleep.2018.01.010 · Cited by 109 · cited 4×
“221,231,234,235 The time to take trazodone for sleep-onset insomnia should be individualized, usuallybetween 30 and 90 minutes before bedtime.”
BackgroundInfluentialArnedt, J. T., Conroy, D. A., Mooney, A., Furgal, A., Sen, A., & Eisenberg, D. (2021) · Sleep · doi:10.1093/sleep/zsaa136 · Cited by 109
Zolpidem in the Treatment of Transient Insomnia: A Double-Blind, Randomized Comparison With Placebo
Roth, T., Roehrs, T., & Vogel, G. (1995) · Sleep · doi:10.1093/sleep/18.4.246 · Cited by 107
Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder
Kunz, D., Dauvilliers, Y., Benes, H., García-Borreguero, D., Plazzi, G., Seboek Kinter, D., Coloma, P., Rausch, M., Sassi-Sayadi, M., & Thein, S. (2023) · CNS Drugs · doi:10.1007/s40263-022-00980-8 · Cited by 107
Yardley, J., Kärppä, M., Inoue, Y., Pinner, K., Perdomo, C. A., Ishikawa, K., Filippov, G., Kubota, N., & Moline, M. L. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.01.048 · Cited by 104
Al-Rasheed, M. M., Fekih‐Romdhane, F., Jahrami, H., Pires, G. N., Saif, Z., Alenezi, A. F., Humood, A. M., Chen, W., Dai, H., Bragazzi, N. L., et al. (2022) · Sleep Medicine · doi:10.1016/j.sleep.2022.06.020 · Cited by 104
Self-citationLewith, G. T., Godfrey, A. D., & Prescott, P. (2005) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2005.11.631 · Cited by 103
Safety of ramelteon in individuals with mild to moderate obstructive sleep apnea
Kryger, M., Wang-Weigand, S., & Roth, T. (2007) · Sleep and Breathing · doi:10.1007/s11325-006-0096-4 · Cited by 98
Randomized Controlled Trial of Telephone-Delivered Cognitive Behavioral Therapy for Chronic Insomnia
Arnedt, J. T., Cuddihy, L., Swanson, L. M., Pickett, S., Aikens, J., & Chervin, R. D. (2013) · Sleep · doi:10.5665/sleep.2448 · Cited by 98
Ancoli-lsrael, S., Krystal, A. D., McCall, W. V., Schaefer, K., Wilson, A., Claus, R., Rubens, R., & Roth, T. (2010) · Sleep · doi:10.1093/sleep/33.2.225 · Cited by 96
GABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 96 · cited 1×
“167”
Mindfulness-Based Interventions for Insomnia: A Meta-Analysis of Randomized Controlled Trials
Wang, Y.-Y., Wang, F., Zheng, W., Zhang, L., Ng, C. H., Ungvari, G. S., & Xiang, Y.-T. (2020) · Behavioral Sleep Medicine · doi:10.1080/15402002.2018.1518228 · Cited by 95 · cited 1×
“Studies involving mindfulness-based intervention protocols compared with controls demonstrate improvements in ISI, 56,95 – 97 PSQI, 97 – 99 and subjective sleep parameters: sleep latency, sleep ef fi ciency, WASO, 97,98 with improvement in mental health parameters during follow-up.”
MethodRoehrs, T. A., Randall, S., Harris, E., Maan, R., & Roth, T. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881111424455 · Cited by 94 · cited 1×
“128 The prevalence of rebound insomnia with discontinuation of zolpidem was not greater than that observed with placebo after daily use for one year, 136 but it may be observed with abrupt discontinuation of higher doses.”
BackgroundCorruble, E., de Bodinat, C., Belaïdi, C., & Goodwin, G. M. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000679 · Cited by 94
Impact of the novel antidepressant agomelatine on disturbed sleep–wake cycles in depressed patients
Quera‐Salva, M., Lemoine, P., & Guilleminault, C. (2010) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1112 · Cited by 92 · cited 2×
“233 Drug interactions, contraindications, side effects, and observations: Agomelatine is metabolized by cytochrome p450 1a2 (CYP1A2) (90”
BackgroundLankford, A., Rogowski, R., Essink, B., Ludington, E. A., Durrence, H. H., & Roth, T. G. (2011) · Sleep Medicine · doi:10.1016/j.sleep.2011.09.006 · Cited by 92
Glass, J. R., Sproule, B. A., Herrmann, N., & Busto, U. E. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31816a9e4f · Cited by 92 · cited 1×
“271,272 Off-label use of this class can generate residual symptoms the next day and compromise everyday situations (re fl exes, ability to drive, etc.).”
BackgroundThe Effect of Mind-Body Therapies on Insomnia: A Systematic Review and Meta-Analysis
Wang, X., Li, P., Pan, C., Dai, L., Wu, Y., & Deng, Y. (2019) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2019/9359807 · Cited by 91 · cited 3×
“This process is grounded on the process of widening body, mental, and environmental perception and awareness.”
BackgroundEfficacy of melatonin for chronic insomnia: Systematic reviews and meta-analyses
Choi, K., Lee, Y. J., Park, S., Je, N. K., & Suh, H. S. (2022) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2022.101692 · Cited by 90
Gao, Y., Ge, L., Liu, M., Niu, M., Chen, Y., Sun, Y., Chen, J., Yao, L., Wang, Q., Li, Z., et al. (2022) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2022.101648 · Cited by 89
Benzodiazepines and Related Sedatives
Peng, L., Morford, K. L., & Levander, X. A. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.08.012 · Cited by 88 · cited 2×
“159,160,162,163 It is noteworthy that the option is also linked to the disease that primarily requires the use of benzodiazepine.”
BackgroundZhao, F.-Y., Fu, Q.-Q., Kennedy, G. A., Conduit, R., Zhang, W., Wu, W., & Zheng, Z. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.01.053 · Cited by 83 · cited 2×
“Systematic reviews and meta-analyses 107 – 114 from the past 4 years evaluating different acupuncture techniques suggest that acupuncture is safe compared with no treat-ment or sham procedures and has produced reduced PSQI scores, increased TST, and sleep ef fi ciency.”
BackgroundEffects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials
Lin, C.-Y., Chiang, C.-H., Tseng, M. M., Tam, K., & Loh, E. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.11.008 · Cited by 83 · cited 2×
“128,250 However, there is an evident need for further studies using it as a treatment of insomnia without psychiatric comorbidities 249,252 and assessing the safety pro fi le of adverse effects using long-term low quetiapine doses.”
BackgroundThe Therapeutic Effect of Aromatherapy on Insomnia: a Meta-Analysis
Tang, Y., Gong, M., Qin, X., Su, H., Wang, Z., & Dong, H. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.03.066 · Cited by 81
Snyder, E., Ma, J., Svetnik, V., Connor, K. M., Lines, C., Michelson, D., & Herring, W. J. (2015) · Sleep Medicine · doi:10.1016/j.sleep.2015.10.007 · Cited by 79
Langade, D., Thakare, V., Kanchi, S., & Kelgane, S. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113276 · Cited by 79
Effects of resistance exercise training and stretching on chronic insomnia
D’Aurea, C. V. R., Poyares, D., Passos, G. S., Santana, M. G., Youngstedt, S. D., Souza, A. A., Bicudo, J., Tufik, S., & de Mello, M. T. (2019) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2018-0030 · Cited by 77 · cited 1×
“127”
Self-citationDATTA, K., TRIPATHI, M., VERMA, M., MASIWAL, D., & MALLICK, H. N. (2021) · The National Medical Journal of India · doi:10.25259/nmji_63_19 · Cited by 77 · cited 1×
“…some studies evaluating the effect of practicing Yoga and Tai-chi point toimprovements in sleep quality, some parameters of sleep architecture, 57,121 – 124 and psychiatric symptoms, 124 the evidence is very limited due to studies with small samples, relatively short follow-up, high response…”
BackgroundLarsson, I., Aili, K., Lönn, M. E., Svedberg, P., Nygren, J., Ivarsson, A., & Johansson, P. (2022) · Sleep Medicine · doi:10.1016/j.sleep.2022.12.021 · Cited by 77
Suvorexant: The first orexin receptor antagonist to treat insomnia
Dubey, A. K., Handu, S. S., & Mediratta, P. K. (2015) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.155496 · Cited by 76
Amitriptyline and EEG Sleep in Depressed Patients: I. Drug Effect
(1978) · Sleep · doi:10.1093/sleep/1.2.149 · Cited by 74
The efficacy of melatonin and melatonin agonists in insomnia – An umbrella review
Low, T. L., Choo, F. N., & Tan, S. M. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.10.022 · Cited by 74 · cited 1×
“Due to the very high af fi nity of doxepin by the H1 receiver, its effect as a selective antagonist of the H1 receiver can be ensured when used at low doses and promoting its hypnotic action (1 to 6mg of doxepin as a hypnotic, compared with 150 to 300 mg of doxepin as an antidepressant).”
BackgroundCognitive-behavioral Therapy of Insomnia
Morin, C. M. (2006) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2006.06.008 · Cited by 72
Karsten, J., Hagenauw, L. A., Kamphuis, J., & Lancel, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116681399 · Cited by 72
Insomnia With Short Sleep Duration
Vgontzas, A. N., & Fernandez-Mendoza, J. (2013) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2013.04.009 · Cited by 72
Nicassio, P. M., Boylan, M. B., & McCabe, T. G. (1982) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1982.tb01494.x · Cited by 71 · cited 2×
“57 “ Alternative ” treatments Biofeedback Biofeedback conducted by Nicasio and colleagues, 104 tested progressive relaxationandneurobiofeedback withelectrodesinthefrontal region, versus simulated neurobiofeedback (placebo) in 40 adult patients.”
BackgroundWho is a candidate for cognitive-behavioral therapy for insomnia?
Smith, M. T., & Perlis, M. L. (2006) · Health Psychology · doi:10.1037/0278-6133.25.1.15 · Cited by 71
Utilização de benzodiazepínicos em idosos brasileiros: um estudo de base populacional
Freire, M. D. B. O., da Silva, B. G. C., Bertoldi, A. D., Fontanella, A. T., Mengue, S. S., Ramos, L. R., Tavares, N. U. L., Pizzol, T. D. S. D., Arrais, P. S. D., Farías, M. R., et al. (2022) · Revista de Saúde Pública · doi:10.11606/s1518-8787.2022056003740 · Cited by 71 · cited 1×
“Therapeutic planning: According to the American Food and Drug Administration (FDA), the recommended dose is 10 mg taken once at night, 30minutes before going to bed, and at least 7hours before the planned time to get up the next morning.”
BackgroundComparison of effects of desipramine and amitriptyline on EEG sleep of depressed patients
Shipley, J. E., Kupfer, D. J., Griffin, S. J., Dealy, R. S., Coble, P. A., McEachran, A. B., Grochocinski, V. J., Ulrich, R., & Perel, J. M. (1985) · Psychopharmacology · doi:10.1007/bf00427316 · Cited by 70
Effects of Mirtazapine on Sleep Polygraphic Variables in Major Depression
Schittecatte, M., Dumont, F., Machowski, R., Cornil, C., Lavergne, F., & Wilmotte, J. (2002) · Neuropsychobiology · doi:10.1159/000067812 · Cited by 70
Quetiapine for primary insomnia: Consider the risks
Modesto‐Lowe, V., Harabasz, A. K., & Walker, S. A. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20031 · Cited by 70 · cited 2×
“128,250 However, there is an evident need for further studies using it as a treatment of insomnia without psychiatric comorbidities 249,252 and assessing the safety pro fi le of adverse effects using long-term low quetiapine doses.”
BackgroundInfluentialMorin, C. M., Bei, B., Bjorvatn, B., Poyares, D. R., Spiegelhalder, K., & Wing, Y. K. (2023) · Sleep Medicine · doi:10.1016/j.sleep.2023.07.001 · Cited by 69
Self-citationSerious adverse effects of cannabidiol (CBD): a review of randomized controlled trials
Dos Santos, R. G., Guimarães, F. S., Crippa, J. A. S., Hallak, J. E. C., Rossi, G. N., Rocha, J. M., & Zuardi, A. W. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1754793 · Cited by 67
Fietze, I., Bassetti, C. L., Mayleben, D. W., Pain, S., Kinter, D. S., & McCall, W. V. (2022) · Drugs & Aging · doi:10.1007/s40266-022-00977-4 · Cited by 67
Wang, M., Wang, C., Tuo, M., Yu, Y., Wang, L., Yu, J., Tan, L., & Chi, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200088 · Cited by 66 · cited 1×
“93 The outcome of CBT-I in patients with more years of chronic insomnia and medication use is inferior to those in the opposite condition.”
BackgroundMorin, C. M., Inoue, Y., Kushida, C., Poyares, D., & Winkelman, J. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.01.023 · Cited by 65
Self-citationGooneratne, N. S., Gehrman, P., Gurubhagavatula, I., Al-Shehabi, E., Marie, E., & Schwab, R. J. (2010) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27991 · Cited by 65
Kryger, M., Roth, T., Wang-Weigand, S., & Zhang, J. (2009) · Sleep and Breathing · doi:10.1007/s11325-008-0196-4 · Cited by 64 · cited 1×
“…with more prolonged use and no evidence of rebound insomnia in 12-month-use studies 189 ; 3) Safety in older patients and patients with comorbidities such as chronic obstructive pulmonary disease (COPD) 200,201 and mild to moderate OSA, 202 without worsening their severities (including hypoxemia).”
BackgroundOrexin receptor antagonists as therapeutic agents for insomnia
Equihua, A. C., de la Herrán-Arita, A. K., & Drucker-Colín, R. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00163 · Cited by 64
Baglioni, C., Bostanova, Z., Bacaro, V., Benz, F., Hertenstein, E., Spiegelhalder, K., Rücker, G., Frase, L., Riemann, D., & Feige, B. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061949 · Cited by 64 · cited 1×
“213 The results are heterogeneous, encompassing effects on reduced sleep latency, 209 reduced sleep latency only in older people, 212 increased TST in comorbid insomnia, 186 reduced early waking, 213 and even the absence of effectiveness.”
BackgroundInsomnia disorder and its reciprocal relation with psychopathology
Lancel, M., Boersma, G. J., & Kamphuis, J. (2021) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2021.02.001 · Cited by 64 · cited 1×
“44,45”
Vgontzas, A. N., Puzino, K., Fernández‐Mendoza, J., Krishnamurthy, V., Basta, M., & Bixler, E. O. (2020) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.8740 · Cited by 61 · cited 3×
“79,221,234,235 It is not recommended for use in children under 18, as safety and effectiveness have not been determined.”
BackgroundTreatment of primary insomnia with melatonin: a double-blind, placebo-controlled, crossover study
Almeida Montes, L. G., Ontiveros Uribe, M. P., Sotres, J. C., & Martin, G. H. (2003) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0324 · Cited by 60
Lee, J., Jung, H. Y., Lee, S. I., Choi, J. H., & Kim, S. G. (2019) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000291 · Cited by 60
Zheng, Y., Lv, T., Wu, J., & Lyu, Y. (2022) · Scientific Reports · doi:10.1038/s41598-022-18776-7 · Cited by 60
Melatonin: From Neurobiology to Treatment
Biggio, G., Biggio, F., Talani, G., Mostallino, M. C., Aguglia, A., Aguglia, E., & Palagini, L. (2021) · Brain Sciences · doi:10.3390/brainsci11091121 · Cited by 59 · cited 2×
“203,204 Exogenous melatonin has been marketed for (cid:1) 30 years, being a chronobiotic suitable for circadian rhythm disorders.”
BackgroundEffect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia.
Zammit, G., Wang-Weigand, S., Rosenthal, M., & Peng, X. (2009) · Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · doi:10.5664/jcsm.27390 · Cited by 59
Acute and Chronic Insomnia: What Has Time and/or Hyperarousal Got to Do with It?
Vargas, I., Nguyen, A. M., Muench, A., Bastien, C. H., Ellis, J. G., & Perlis, M. L. (2020) · Brain Sciences · doi:10.3390/brainsci10020071 · Cited by 58
Linh, T. T. D., Ho, D. K. N., Nguyen, N. N., Hu, C., Yang, C., & Wu, D. (2023) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2023.101833 · Cited by 58
Quetiapine for primary insomnia: a double blind, randomized controlled trial.
Tassniyom, K., Paholpak, S., Tassniyom, S., & Kiewyoo, J. (2010) · PubMed · Cited by 57
Effects of Quetiapine on Sleep in Nonpsychiatric and Psychiatric Conditions
Wine, J. N., Sanda, C., & Caballero, J. (2009) · Annals of Pharmacotherapy · doi:10.1345/aph.1l320 · Cited by 56 · cited 3×
“243,248,249 In 2010, an RCT evaluated the use of 25mg quetiapine at night for the treatment of primary insomnia.”
BackgroundMoline, M. L., Zammit, G. K., Cheng, J. Y., Perdomo, C. A., Kumar, D., & Mayleben, D. W. (2021) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.9150 · Cited by 56 · cited 1×
“181 Drug interactions, contraindications, side effects: The effective half-life is 17 – 19hour and reaches peak concentration in (cid:1) 1 to 3hour.”
BackgroundLouzada, L. L., Machado, F. V., Quintas, J. L., Ribeiro, G. A., Silva, M. V., da Silva, D. L. M., Gonçalves, B. S. B., Nóbrega, O. D. T., & Camargos, E. F. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01191-3 · Cited by 56
Rösner, S., Englbrecht, C., Wehrle, R., Hajak, G., & Soyka, M. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010703.pub2 · Cited by 54
Suraev, A. S., Grunstein, R. R., Marshall, N. S., D'Rozario, A. L., Gordon, C. J., Bartlett, D. J., WONG, K. K. H., Yee, B. J., Vandrey, R. G., Irwin, C. G., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-034421 · Cited by 54
Self-help treatment for insomnia through television and book: A randomized trial
van Straten, A., Cuijpers, P. J., Smit, F., Spermon, M., & Verbeek, I. (2008) · Patient Education and Counseling · doi:10.1016/j.pec.2008.07.050 · Cited by 52
Insomnia symptoms predict both future hypertension and depression
Dong, Y., & Yang, F. M. (2019) · Preventive Medicine · doi:10.1016/j.ypmed.2019.02.001 · Cited by 52
Xia, L., Zhang, P., Niu, J.-W., Ge, W., Chen, J., Yang, S., Su, A.-X., Feng, Y.-Z., Wang, F., Chen, G., et al. (2021) · Nature and Science of Sleep · doi:10.2147/nss.s310698 · Cited by 52 · cited 1×
“Using techniques derived from the cognitive and behavioral approach and practices to promote relaxation, 47,48 the literature has documented well CBT-I ’ s effectiveness in treating insomnia co-morbid with medical and psychiatric conditions.”
MethodErman, M. K., Zammit, G. K., Rubens, R., Schaefer, K., Wessel, T. C., Amato, D. A., Caron, J., & Walsh, J. K. (2008) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.27185 · Cited by 52
Antidepressant and Antipsychotic Drugs
Krystal, A. D. (2010) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2010.08.010 · Cited by 51
Roth, T., Krystal, A., Steinberg, F. J., Singh, N. N., & Moline, M. (2013) · Sleep · doi:10.5665/sleep.2370 · Cited by 49
Furey, S. A., Hull, S. G., Leibowitz, M. T., Jayawardena, S., & Roth, T. G. (2014) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.4110 · Cited by 49
Xu, H., Zhang, C., Qian, Y., Zou, J., Li, X., Liu, Y., Zhu, H., Meng, L., Liu, S., Zhang, W., et al. (2020) · Sleep Medicine · doi:10.1016/j.sleep.2020.10.018 · Cited by 49
Lü, Y., Zhu, H., Wang, Q., Tian, C., Lai, H., Hou, L., Liu, Y., Gao, Y., Liu, M., Yang, F., et al. (2022) · Sleep Medicine · doi:10.1016/j.sleep.2022.03.012 · Cited by 49
Zhang, J., He, Y., Huang, X., Liu, Y., & Yu, H. (2020) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2020.101253 · Cited by 48
Paulos-Guarnieri, L., Linares, I. M. P., & El Rafihi-Ferreira, R. (2022) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2021.11.001 · Cited by 48 · cited 4×
“55,68 When compared with CBT-I, ACT showed no differences in subjective sleep parameters.”
BackgroundMethodInfluentialSelf-citationChapoutot, M., Peter‐Derex, L., Schoendorff, B., Faivre, T., Bastuji, H., & Putois, B. (2021) · Journal of Sleep Research · doi:10.1111/jsr.13199 · Cited by 47 · cited 1×
“55,68 Chapoutot and colleagues 94 observed reduced hypnotics, Z-drugs, and BZDs consumption in response to ACT.”
BackgroundCannabinoids in the Treatment of Insomnia Disorder: A Systematic Review and Meta-Analysis
Bhagavan, C., Kung, S., Doppen, M., John, M., Vakalalabure, I., Oldfield, K., Braithwaite, I., & Newton-Howes, G. (2020) · CNS Drugs · doi:10.1007/s40263-020-00773-x · Cited by 45 · cited 1×
“259 Another meta-analysis, with more than 5,000 patients, evaluated the impact of different cannabinoids onpatientswith sleepcomplaints under various medical conditions.”
BackgroundMarupuru, S., Arku, D., Campbell, A., Slack, M. K., & Lee, J. K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175138 · Cited by 45 · cited 1×
“221 In addition, doxepin is actually a mixture of two chemical forms, one of which (and its active metabolites) has a shorter half-life (8 to 15hour) than the other, which has the traditionally long half-life tricyclic antidepressants (24hour).”
BackgroundZhang, C., Liu, Y., Guo, X., Liu, Y., Shen, Y., & Ma, J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.4866 · Cited by 45
Research works printed but not linked: 8
- AASM International Classification of Sleep Disorders Darien, IL American Academy of Sleep Medicine 2014
- Leeflang M M Davenport C Bossuyt P Chapter 6: Defining the review question. Draft version (14 January 2022) 2 ed. London Cochrane 2022
- Perlis M Aloia M Kuhn BBehavioral treatments for sleep disorders: A comprehensive primer of behavioral sleep medicine intervention: Academic Press; 2010
- Hayes S C Strosahl K D Wilson K G Acceptance and commitment therapy: An experiential approach to behaviour change New York The Guiford Press 1999
- Kabat-Zinn J Catastrophe Living: Using the Wisdom of your Body and Mind to Face Stress, Pain, and Illness New York Delacorte Press 1990
- Seyffert M Lagisetty P Landgraf J Internet-Delivered Cognitive Behavioral Therapy to Treat Insomnia: A Systematic Review and Meta-Analysis PLoS One 2016 11 02 e0149139 26867139 PMC4750912 · DOI · Paper page
- Bacelar A Pinto L R Jr Insônia - Do diagnóstico ao tratamento São Caetano do Sul 2019172 p.
- A review of the pharmacological and clinical profile of mirtazapine [press release] US Neva Press 2001
Cited by
Pires, G. N., Arnardóttir, E. S., Bailly, S., & McNicholas, W. T. (2024) · Journal of Sleep Research · doi:10.1111/jsr.14163 · Cited by 12
“Since then, this method has been extensively utilized, including in sleep medicine (Berezin et al., 2021; Boerner et al., 2015; Drager et al., 2023; Murphie et al., 2018; Pearson et al., 2020; Studart-Pereira et al., 2023).”
Self-citationInsomnia and its treatments—trend analysis and publication profile of randomized clinical trials
Kakazu, V. A., Assis, M., Bacelar, A., Bezerra, A. G., Ciutti, G. L. R., Conway, S. G., Galduróz, J. C. F., Drager, L. F., Khoury, M. P., Leite, I. P. A., et al. (2024) · npj Biological Timing and Sleep · doi:10.1038/s44323-024-00014-0 · Cited by 6
“Regarding pharmacological interventions, thisincludesthedevelopmentandapprovalofnewdrugclasses,suchasdual orexinreceptorantagonists(DORAs) 11 – 13 .”
InfluentialSelf-citationKakazu, V. A., Assis, M., Bacelar, A., Bezerra, A. G., Ciutti, G. L. R., Conway, S. G., Galduróz, J. C. F., Drager, L. F., Khoury, M. P., Leite, I. P. A., et al. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1600767 · Cited by 5
Self-citationCarvalho, F., Tonon, A. C., Hidalgo, M. P., Martins Costa, M., & Mengue, S. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405838 · Cited by 4
Chi, J.-Y., Zhu, R.-X., Cheng Ann, C. H. E. N., Xu, R.-L., Lyu, C.-Z., Yao, J.-X., Fu, M.-Q., Wang, D., & Du, G.-S. (2025) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2025.10.006 · Cited by 3
Metadata
- Authors
- Drager, L. F., Assis, M., Bacelar, A. F. R., Poyares, D. L. R., Conway, S. G., Pires, G. N., de Azevedo, A. P., Carissimi, A., Eckeli, A. L., Pentagna, Á., Almeida, C. M. O., Franco, C. M. R., Sobreira, E. S. T., Stelzer, F. G., Mendes, G. M., Minhoto, G. R., Linares, I. M. P., Sousa, K. M. M., Gitaí, L. L. G., Sukys-Claudino, L., Sobreira-Neto, M. A., Zanini, M. A., Margis, R., & Martinez, S. C. G.
- Affiliations
- Universidade de São Paulo (BR)
- Associação Brasileira do Sono, São Paulo, SP, Brazil.
- Departamento de Psicobiologia, Universidade Federal de São Paulo, São Paulo, Brazil.
- Instituto do Sono (BR)
- Instituto de Psiquiatria (IPq), Universidade de São Paulo, São Paulo, SP, Brazil.
- Faculdade Dom Bosco, Porto Alegre, RS, Brazil.
- Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil.
- Universidade do Estado do Amazonas (BR)
- Universidade Federal de Pernambuco (BR)
- Universidade Federal do Ceará (BR)
- Instituto de Especialidades e Sono, Goiânia, GO, Brazil.
- Pontifícia Universidade Católica do Paraná (BR)
- Universidade Federal de São Paulo (BR)
- Faculdade de Medicina, Universidade Federal de Alagoas, AL, Brazil.
- Universidade Federal de Santa Catarina (BR)
- Instituto de Assistência Médica ao Servidor Público Estadual (IAMPSE), São Paulo, SP, Brazil.
- Private clinic, Porto Alegre, RS, Brazil.
- Universidade Estadual de Campinas (UNICAMP) (BR)
- Corresponding author
- Drager, Luciano Ferreira
- ORCID
- Drager, Luciano Ferreira
- Assis, Márcia
- Bacelar, Andrea Frota Rego
- Poyares, Dalva Lucia Rollemberg
- Conway, Silvia Gonçalves
- Pires, Gabriel Natan
- de Azevedo, Alexandre Pinto
- Carissimi, Alicia
- Eckeli, Allan Luiz
- Pentagna, Álvaro
- Almeida, Carlos Maurício Oliveira
- Franco, Clélia Maria Ribeiro
- Sobreira, Emmanuelle Silva Tavares
- Stelzer, Fernando Gustavo
- Mendes, Giuliana Macedo
- Minhoto, Gisele Richter
- Linares, Ila Marques Porto
- Sousa, Ksdy Maiara Moura
- Gitaí, Livia Leite Góes
- Sukys-Claudino, Lucia
- Sobreira-Neto, Manoel Alves
- Zanini, Marcio Andrei
- Margis, Regina
- Martinez, Sandra Cristina Gonçalves
- Venue
- Sleep Science
- Publisher
- Georg Thieme Verlag KG
- Published
- 2023-10
- Volume
- 16
- Issue
- S 02
- Pages
- 507-549
- ISSN
- 1984-0063 (ISSN-L)
- 1984-0659
- PMC
- PMC10869237
- OpenAlex
- W4388892302
- Cited by
- 25
- References
- 268
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 7
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Sleep Science (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- chronic insomnia, insomnia diagnosis, insomnia treatment, adults, sleep medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.